about
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerBladder Sparing Approaches for Muscle-Invasive Bladder CancersA phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer.Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United KingdomThe systemic treatment of advanced and metastatic bladder cancer.Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyBladder reconstruction: The past, present and future.The international normalized ratio does not reflect bleeding risk in esophageal variceal hemorrhage.Molecular markers in bladder cancer.Management of muscle invasive bladder cancer--British approaches to organ conservation.Molecular pathways in bladder cancer: part 2.Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder.Pillcam ESO(®) is more accurate than clinical scoring systems in risk stratifying emergency room patients with acute upper gastrointestinal bleedingMolecularly targeted therapeutics for breast cancer.Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)Biology of testicular germ cell tumors.Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea.The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance.Gene expression profiling in bladder cancer identifies potential therapeutic targetsBiology of germ cell tumors.The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter.Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).The West Midlands Bladder Cancer Prognosis Programme: rationale and design.Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.Outcome among patients with acute renal failure needing continuous renal replacement therapy: A single center study.Successful treatment of radiation nephropathy with angiotensin II blockade.Access to kidney transplantation among patients insured by the United States Department of Veterans Affairs.BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients.The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers.Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX.Ketamine-induced biliary dilatation: from Hong Kong to New York.The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004).
P50
Q27853235-629E0077-8A0F-433C-9E38-F698EA8EDE20Q28072814-A023A5D9-C5E5-4781-86E0-22C5A231FD5FQ33361999-EA3B35A4-0755-4665-BF9C-98A8BA871CD2Q33976936-7685453D-C1FB-4743-929D-54D16E502961Q34861218-36958109-362C-4375-A23A-B8FA8FFB4FEBQ35193683-70AB027C-3B4C-4D2D-BAC1-893E0ADE3B60Q35771672-CFD98D25-A8D6-4473-BD54-2856522D6455Q35803619-220C2E05-9E7A-46EE-9BB5-09FDEA8E806BQ35973813-06AF27EB-2048-447D-AEC0-3EEF99CE999CQ36015966-68687947-F0C5-47D2-8582-EAB75F0082DBQ36015974-6FBFB5C9-767D-42C5-AD6D-18161A250DF8Q36037512-D68AEFC4-A6B8-47EF-8459-5F4CB11219AAQ36610569-81F39CC7-6B97-426B-8973-7189CB77B6AAQ36649097-2909CCCE-B927-42A6-8516-3B74FF14F17CQ36761888-B9ECA6AD-B28D-4D07-A31E-C043D3F090DAQ36879839-1CB4F08E-5A9A-44E0-A710-C996ED1A5CB3Q37121672-DE307B58-3FBD-4312-8816-D24C5C138480Q37300035-656F420A-04BB-48BB-807E-402F1FEECAB7Q37410675-382C39AC-260B-4648-90E0-B685A1E0AE3EQ37696214-A666EF13-BDE5-4A2C-8FA8-8161C0F5B945Q37718676-BCB7FFBB-E672-40B7-8F03-2A9749AFA676Q37875403-3276F901-5CF3-403C-8FEB-AE3E9E44F227Q38391671-8745DF36-FED8-4845-B2EC-15FD04ACD288Q38396913-7346684E-3524-4D78-BAF0-52E2226A53BEQ38654974-BEDF8FED-7EDC-4970-B0A1-970B46E3407BQ38799227-297C8D87-A649-4EBF-B553-B4A26E88D208Q38892734-ECC8DF7D-D0E0-4606-81B0-173616349B7AQ39714017-68E69636-3E29-48BD-95E4-386612A4445BQ39947406-B312BFBD-160D-4196-A536-7A9E17C40608Q40294732-F18BDB48-F7F7-4CC0-BB65-808EAA9B87A1Q40545094-D62C018D-3EB3-4D48-9191-7D4C7EAD355CQ43719040-73EFB0A9-FF13-4A23-BB42-D5D031D92D1CQ44052466-2DCDCE6B-246F-4AEB-9A59-5334A1BD6B15Q44263752-7802AC36-941E-4797-AD48-19241FEE9283Q45332252-7A3143B0-8BEE-43BB-BFB1-0754B488A1A2Q45423862-5BF12138-F1A9-4DB9-967C-8CF3F074FEEAQ46011641-56605E96-DC65-4677-BAB5-0DD72AA7E342Q47109893-FEF59DE3-8B4C-4629-975B-868AC814A957Q48209413-33344B33-0BBA-483B-839B-037554FEC2D0Q51167495-2C7F740F-2C48-4974-B9CC-CCFF61741193
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Syed A Hussain
@nl
Syed A Hussain
@sl
Syed A. Hussain
@en
Syed A. Hussain
@es
type
label
Syed A Hussain
@nl
Syed A Hussain
@sl
Syed A. Hussain
@en
Syed A. Hussain
@es
prefLabel
Syed A Hussain
@nl
Syed A Hussain
@sl
Syed A. Hussain
@en
Syed A. Hussain
@es
P108
P106
P1153
7403344985
P31
P496
0000-0003-1552-511X